BG
AXSM icon

Bellevue Group’s Axsome Therapeutics AXSM Stock Holding History

Bellevue Group’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$658K Sell
2,689
-492
-15% -$107K 0.01% 106
2026
Q1 		$538K Sell
3,181
-24,419
-88% -$4.22M 0.01% 113
2025
Q4 		$5.04M Sell
27,600
-24,735
-47% -$3.45M 0.1% 75
2025
Q3 		$6.36M Sell
52,335
-3,918
-7% -$441K 0.13% 69
2025
Q2 		$5.87M Sell
56,253
-40,154
-42% -$4.25M 0.13% 78
2025
Q1 		$11.2M Sell
96,407
-22,523
-19% -$2.57M 0.25% 71
2024
Q4 		$10.1M Sell
118,930
-248,251
-68% -$22.8M 0.19% 80
2024
Q3 		$33M Sell
367,181
-149,352
-29% -$13M 0.53% 57
2024
Q2 		$41.6M Sell
516,533
-168,943
-25% -$12.5M 0.68% 37
2024
Q1 		$54.7M Buy
685,476
+50,104
+8% +$4.21M 0.83% 32
2023
Q4 		$50.6M Buy
635,372
+3,885
+0.6% +$260K 0.77% 42
2023
Q3 		$44.1M Buy
631,487
+57,124
+10% +$4.27M 0.71% 42
2023
Q2 		$41.3M Buy
574,363
+133,013
+30% +$9.81M 0.59% 56
2023
Q1 		$27.2M Buy
441,350
+4,692
+1% +$308K 0.4% 67
2022
Q4 		$33.7M Sell
436,658
-59,866
-12% -$3.58M 0.45% 64
2022
Q3 		$22.2M Sell
496,524
-320,617
-39% -$16M 0.32% 78
2022
Q2 		$31.3M Buy
817,141
+97,659
+14% +$3.09M 0.44% 64
2022
Q1 		$29.8M Buy
719,482
+67,545
+10% +$2.09M 0.35% 82
2021
Q4 		$24.6M Sell
651,937
-101,008
-13% -$3.72M 0.25% 97
2021
Q3 		$24.8M Buy
752,945
+400,924
+114% +$15.6M 0.25% 98
2021
Q2 		$23.7M Buy
+352,021
New +$21.1M 0.23% 102

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Bellevue Group's AXSM Position: Q2 2026 in Review

Bellevue Group reduced its Axsome Therapeutics (AXSM) stake by 15% in Q2 2026, selling an estimated $107K and leaving 2,689 shares worth $658K. The position accounts for 0.01% of the portfolio, ranked #106.

Bellevue Group first reported a position in AXSM in Q2 2021 and has held it in 21 quarters since. The position peaked at $54.7M in Q1 2024. 505 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Bellevue Group held 2,689 shares of Axsome Therapeutics worth $658K as of Q2 2026.
  • Bellevue Group sold 492 Axsome Therapeutics shares in Q2 2026, an estimated $107K.
  • Axsome Therapeutics made up 0.01% of Bellevue Group's portfolio in Q2 2026, its #106 holding.
  • Bellevue Group first reported a position in Axsome Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • Bellevue Group's Axsome Therapeutics position peaked at $54.7M in Q1 2024.
  • 505 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Bellevue Group's 13F filing for Q2 2026, filed 14 Aug 2026.